Tobira Therapeutics, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Manalapan NJ United States (2006)
Status: Acquired by Allergan PLC (2015) (2016) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2009
NCT01092104
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

AIDS Dementia Complex (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Dementia (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 3)

Hepatic Insufficiency (Phase 1)

HIV Infections (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 2)

Insulin Resistance (Phase 2)

Liver Cirrhosis (Phase 3)

Liver Diseases (Phase 2)

Liver Failure (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Prediabetic State (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 16